Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy.

@article{Lui2010CosteffectivenessAO,
  title={Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy.},
  author={Yanni Yan-Ni Lui and Kelvin Kam-Fai Tsoi and Vincent Wai-Sun Wong and Jia-Horng Kao and Jin-Lin Hou and E K Teo and Rosmawati Mohamed and Teerha Piratvisuth and Kwang-hyub Han and Ulrike Mihm and Grace Lai-Hung Wong and Henry L. Y. Chan},
  journal={Antiviral therapy},
  year={2010},
  volume={15 2},
  pages={145-55}
}
BACKGROUND The roadmap approach is recommended to guide chronic hepatitis B treatment. We evaluated the cost-effectiveness of various treatment strategies in the global market. METHODS Lamivudine and telbivudine were tested in roadmap models with switch-to tenofovir if HBV was detectable at week 24 or add-on tenofovir if resistance developed at year 1. Tenofovir and entecavir were tested as continuous monotherapy. In the reference arm, lamivudine was used with add-on tenofovir if resistance… CONTINUE READING
17 Citations
35 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 35 references

Telbivudine versus lamivudine in patients with chornic hepatitis

  • CL Lai, E Gane, YF Liaw
  • B. N Engl J Med
  • 2007
Highly Influential
6 Excerpts

Similar Papers

Loading similar papers…